Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

BACKGROUND: Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among patients with active PsA. This analysis evalu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: McInnes, Iain B., Mease, Philip J., Schett, Georg, Kirkham, Bruce, Strand, Vibeke, Williams, Nicole, Fox, Todd, Pricop, Luminita, Jugl, Steffen M., Gandhi, Kunal K.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5992664/
https://ncbi.nlm.nih.gov/pubmed/29880010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-018-1610-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky